Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433148 | 0.81 | BTK (0.38) | NSD3DDB1CRBNMAPTNPC1 | |
| SCHEMBL31433152 | 0.79 | MAOA (0.44) | NSD3DDB1CRBNHPGDMAPT | |
| SCHEMBL31433140 | 0.78 | CNR1 (0.39) | NSD3HPGDMAPTNPC1RAB9A | |
| SCHEMBL31433126 | 0.78 | BTK (0.44) | NSD3DDB1CRBNMAPTNPC1 | |
| SCHEMBL5688136 | 0.77 | POLB (0.39) | NSD3DDB1CRBNHPGDMAPT | |
| SCHEMBL31433109 | 0.76 | EGFR (0.40) | NSD3MAPTNPC1RAB9ALMNA | |
| SCHEMBL31433149 | 0.76 | MAOB (0.43) | DDB1CRBNMAPTNPC1RAB9A | |
| SCHEMBL31433153 | 0.76 | NPC1 (0.39) | NSD3HPGDMAPTNPC1RAB9A | |
| SCHEMBL31433284 | 0.76 | NPC1 (0.38) | NSD3DDB1CRBNMAPTNPC1 | |
| SCHEMBL31433080 | 0.76 | MAPK1 (0.44) | HPGDMAPTLMNAKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638701-A | Method for asymmetric hydrogenation of pyrazolopyrimidine polyazo aromatic compound by manganese catalysis | 中国科学院大连化学物理研究所 | 2025-03-18 | — | — | CN | disclosed |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2023-08-10 | — | — | US | disclosed |
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | NSD3 1990/4885DDB1 3025/4885CRBN 1834/4885 |
| US-20230248833-A1 | COMPOUND HAVING BTK KINASE DEGRADING ACTIVITY, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREFOR | BTK, WEE1, WEE2 | NSD3 3966/4885DDB1 3863/4885CRBN 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.